Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Barclays upgrades Burberry to 'equalweight', hikes price target

(Sharecast News) - Barclays upgraded Burberry on Tuesday to 'equalweight' from 'underweight' and hiked the price target to 1,000p from 720p as it said its key concerns around the dilution of the brand equity now appear less likely to materialise. Barclays said it was updating its estimates following the reporting season and upgrading the name for two main reasons.

Firstly, the bank said it thinks the company's high-end brand positioning is no longer at risk.

Barclays turned 'underweight' on Burberry last year as it was worried that the lack of a disciplined full-price strategy, the markdown initiatives, high exposure to outlets and potential change of strategy from the new management could put the brand's high-end luxury positioning at risk.

However, it noted that over the past few months, these risks don't appear to have materialised.

"The markdowns activity that took place in November 2024 didn't seem to dilute the brand image. The new brand strategy focusing on Burberry's core offering (outerwear/ scarves) is more in line with the brand's DNA and the most recent marketing campaigns and fashion shows seem to be having better tractions as flagged during the May-25 conference call (the brand has reached its higher level of brand desirability and brand affinity in the past three years - Kantar metrics)," it said.

"Even if it is still early to gauge whether the new products will translate into a success when they reach the stores in calendar H2, we think that navigating a phase of markdowns without damaging the brand equity is already a positive."

Secondly, Barclays said that after turning loss-making in H1-25 at the EBIT level, the brand returned to profit in H2-25 and should see further EBIT improvement in FY-26.

"The higher amount of cost savings announced should also provide some cushion in the event of additional macro headwinds," Barclays said.

"We keep in mind, however, that the brand transformation remains at an early stage and that top-line growth could remain negative in the short-term."

At 1015 BST, the shares were up 2.9% at 990p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.